NCT05032690View on ClinicalTrials.gov

Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib Capsule

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 19, 2022

Primary Completion Date

June 25, 2022

Study Completion Date

June 25, 2022

Conditions
Healthy Participants
Interventions
DRUG

Bosutinib capsule

Bosutinib four 25 mg capsule taken after a high-fat and high calorie breakfast

DRUG

Bosutinib capsule

Bosutinib 100 mg capsule taken after a high-fat and high calorie breakfast

DRUG

Bosutinib

Bosutinib 100 mg capsule taken after an overnight fast of at least 10 hours

DRUG

Bosutinib capsule

Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit - Brussels, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05032690 - Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib Capsule | Biotech Hunter | Biotech Hunter